Screening for hemochromatosis by measuring ferritin levels: a more effective approach
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Because the penetrance of HFE hemochromatosis is low, traditional population screening measuring the transferrin saturation is unlikely to be cost-effective because the majority of subjects detected neither have clinical disease nor are likely to develop it. Three independent studies show that only patients with serum ferritin concentrations more than 1000 μg/L are at risk for cirrhosis, one of the main morbidities of hemochromatosis. Among 29 699 white subjects participating in the Scripps/Kaiser hemochromatosis study, only 59 had serum ferritin levels more than 1000 μg/L; 24 had homozygous mutant or compound heterozygous mutant HFE genotypes. In all but 5 of the other subjects, the causes of elevated ferritin were excessive alcohol intake, cancer, or liver disease. Screening for hemochromatosis with serum ferritin levels will detect the majority of patients who will be clinically affected and may detect other clinically significant disease in patients who do not have hemochromatosis genotypes. Because the ferritin level of the majority of adult homozygotes for HFE mutations does not rise over long periods of time, excluding subjects with serum ferritin levels less than or equal to 1000 μg/L should not result in missed opportunities for early treatment of patients who could benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA
Beutler, E., Felitti, V. J., Koziol, J. A., Ho, N. J., & Gelbart, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07447-0 · Cited by 823
Self-citationWrede, C. E., Buettner, R., Bollheimer, L. C., Schölmerich, J., Palitzsch, K.-D., & Hellerbrand, C. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02083 · Cited by 161
Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene
Waalen, J., Felitti, V., Gelbart, T., Ho, N. J., & Beutler, E. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.6.522 · Cited by 71
Self-citation
Cited by
Serum ferritin: Past, present and future
Wang, W., Knovich, M. A., Coffman, L. G., Torti, F. M., & Torti, S. V. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.03.011 · Cited by 879
Knovich, M. A., Storey, J. A., Coffman, L. G., Torti, S. V., & Torti, F. M. (2009) · Blood Reviews · doi:10.1016/j.blre.2008.08.001 · Cited by 627
EASL clinical practice guidelines for HFE hemochromatosis
European Association for the Study of the Liver (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.03.001 · Cited by 587
Ruddell, R. G., Hoang‐Le, D., Barwood, J. M., Rutherford, P. S., Piva, T. J., Watters, D. J., Santambrogio, P., Arosio, P., & Ramm, G. A. (2009) · Hepatology · doi:10.1002/hep.22716 · Cited by 298
Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., et al. (2021) · Blood · doi:10.1182/blood.2020007445 · Cited by 297
Metadata
- Authors
- Waalen, J., Felitti, V. J., Gelbart, T., & Beutler, E.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-04-01
- Volume
- 111
- Issue
- 7
- Pages
- 3373-3376
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2029325051
- Cited by
- 105
- References
- 3
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for hemochromatosis by measuring ferritin levels: a more effective approach. https://app.cochat.ai/papers/10.1182/blood-2007-07-102673
- The paper
- Waalen, J., Felitti, V. J., Gelbart, T., & Beutler, E. (2008). Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood. https://doi.org/10.1182/blood-2007-07-102673
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.